OSR Health, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by OSR Health, Inc. on August 19, 2026. The report addresses a critical corporate governance event regarding the listing status of the Company's securities on The Nasdaq Stock Market LLC.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on regulatory compliance regarding stock listing standards rather than financial performance metrics.
Material Changes
- Delisting Determination: On August 19, 2026, Nasdaq notified the Company that it will delist its common stock (OSRH) and redeemable warrants (OSRHW) from the Nasdaq Capital Market.
- Non-Compliance Reason: The Company failed to meet Nasdaq Listing Rule 5550(a)(2), which requires a minimum closing bid price of $1.00 per share. Despite a compliance period extending to August 31, 2026, the Company could not achieve the required price for ten consecutive trading days.
- Trading Suspension: Trading in the Company's securities is scheduled to be suspended at the opening of business on August 26, 2026.
Outlook, Risks, and Management Commentary
- Appeal Process: The Company intends to request a hearing before a Nasdaq Hearings Panel by 4:00 p.m. Eastern Time on August 26, 2026.
- Impact of Appeal: A timely hearing request is expected to stay the filing of the Form 25-NSE (which formally removes securities from listing), but it will not stay the suspension of trading scheduled for August 26, 2026.
- Risks: There is no assurance that the hearing request will result in continued listing or that the Company will regain compliance. If the Panel denies the request or no hearing is requested, Nasdaq will proceed with the formal delisting.
Investor Verification Checklist
- Confirm the status of the hearing request with the Nasdaq Hearings Panel by August 26, 2026.
- Monitor the suspension of trading on August 26, 2026, and the subsequent availability of the stock on alternative markets (e.g., OTC).
- Review the Company's plan to regain compliance with the $1.00 minimum bid price requirement.
- Verify the filing of Form 25-NSE by Nasdaq if the appeal is unsuccessful.